Étiquette : delta-9 THC

Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol. Pharmacokinetics and Pharmacodynamics in Healthy Adults : A Randomized Clinical Trial, C. Austin Zamarripa et al., 2023

Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol. Pharmacokinetics and Pharmacodynamics in Healthy Adults : A Randomized Clinical Trial C. Austin Zamarripa, PhD; Tory R. Spindle, PhD; Renuka Surujunarain; Elise M. Weerts, PhD; Sumit Bansal, PhD; Jashvant D. Unadkat, PhD; Mary F. Paine, PhD; Ryan Vandrey, PhD Jama Network Open, 2023, 6, (2), e2254752, 1-15. doi : 10.1001/jamanetworkopen.2022.54752 Key Points Question : Are there acute pharmacokinetic or pharmacodynamic differences between oral ingestion of a Δ9-tetrahydrocannabinol (Δ9-THC)- dominant cannabis extract compared with a cannabidiol (CBD)-dominant extract at the same Δ9-THC dose (20 mg) in healthy adults who use cannabis infrequently? Findings : In this randomized clinical trial including 18 [...]

Lire la suite

Cannabis containing equivalent concentrations of delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC‐dominant cannabis, Nadia R. P. W. Hutten et al., 2022

Cannabis containing equivalent concentrations of delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC‐dominant cannabis Nadia R. P. W. Hutten, T. R. Arkell, F. Vinckenbosch, J. Schepers, R. C. Kevin, E. L. Theunissen, K. P. C. Kuypers, I. S. McGregor, J. G. Ramaekers Psychopharmacology, 2022, 239, 3731–3741 Doi : 10.1007/s00213-022-06248-9   Abstract Rationale : Delta-9-tetrahydrocannabinol (THC), an active component of cannabis, can cause anxiety in some users during intoxication. Cannabidiol (CBD), another constituent of cannabis, has anxiolytic properties suggesting that cannabis products containing CBD in addition to THC may produce less anxiety than THC-only products. Findings to date around this issue have been inconclusive and [...]

Lire la suite

Mort du chercheur Raphael Mechoulam, chantre du chanvre médical, Libération, 13 mars 2023

Mort du chercheur Raphael Mechoulam, chantre du chanvre médical par Charles Delouche-Bertolasi Libération,13 mars 2023 Pionnier de l’utilisation médicale du cannabis, le scientifique israélien est mort le 9 mars à Jérusalem, à l’âge de 92 ans. Entre autres découvertes, il est celui qui a réussi en 1964 à isoler le THC, principe actif du cannabis. Raphael Mechoulam, lors d'une conférence à Tel Aviv, en mars 2016. (JACK GUEZ/AFP) Depuis quelques jours, certains fumeurs de joints dédient leurs exhalaisons à un homme, qui vient de s’éteindre en Israël à l’âge de 92 ans : le docteur Raphael Mechoulam, chimiste et scientifique, chercheur pionnier à l’origine de la découverte du delta-9 [...]

Lire la suite

Raphael Mechoulam, « père de la recherche sur le cannabis », est décédé à l’âge de 92 ans, Aurelien Bernard, Newsweed, 2023

Raphael Mechoulam, « père de la recherche sur le cannabis », est décédé à l’âge de 92 ans Aurélien BERNARD Newsweed.org, 10 mars 2023 Le célèbre scientifique spécialiste du cannabis Raphael Mechoulam est décédé à l’âge de 92 ans. La nouvelle a été annoncée par des amis et des collègues qui ont fait part de leurs condoléances et de leurs hommages. « C’est un jour très triste pour moi, pour la communauté scientifique et pour la communauté du cannabis. Le professeur Raphael Mechoulam, que nous appelions Raphi, était l’un des plus grands scientifiques que j’aie jamais rencontrés, mon professeur et mon mentor à bien des égards. Je crois [...]

Lire la suite

Cannabinoids and Endocannabinoids, and Prospective Modulation of EC Signaling in Neurodegenerative, Cardiovascular and Allied Disorders, Vinod Nikhra, 2019

Cannabinoids and Endocannabinoids, and Prospective Modulation of EC Signaling in Neurodegenerative, Cardiovascular and Allied Disorders Dr Vinod Nikhra Preprint, May 2019 Doi : 10.13140/RG.2.2.36649.24165   ABSTRACT CANNABIS USE AND AVAILABILITY: The Cannabis derivatives have been used for recreational and medicinal purposes since ancient times. Because of the additive potential of cannabis products, their sale, possession and use are variously regulated in different countries throughout the world. Still as a psychoactive drug, cannabis continues to find extensive favour among recreational and medical users in the USA and other countries having led to decriminalise cannabis use for recreational and medicinal purposes. ECS: RECEPTORS, LIGANDS AND SIGNALING: The endocannabinoid system comprises [...]

Lire la suite

Mechoulam on the Future of Cannabinoid Research, Martin A. LEE, Project CBD, 2023

MECHOULAM ON THE FUTURE OF CANNABINOID RESEARCH The father of cannabis science emphasized three key areas to pursue By Martin A. Lee on March 15, 2023 I was fortunate to cross paths with Raphael Mechoulam, “the father of cannabis research,” at several science conferences over the years. The most memorable occasion was the 22nd annual meeting of the International Cannabinoid Research Society (ICRS) in Freiburg, Germany, in July 2012. Mechoulam delivered a plenary speech at the symposium, addressing the future of cannabinoid research and key areas of study that should be pursued. It was exactly fifty years earlier, in 1962, when Mechoulam launched his [...]

Lire la suite

Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system ? A systematic review, John M McPartland et al., 2014

Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review John M McPartland, Marnie Duncan, Vincenzo Di Marzo and Roger G Pertwee British Journal of Pharmacology, 2015, 172, 737-753. Doi : 10.1111/bph.12944   Based upon evidence that the therapeutic properties of Cannabis preparations are not solely dependent upon the presence of Δ9-tetrahydrocannabinol (THC), pharmacological studies have been recently carried out with other plant cannabinoids (phytocannabinoids), particularly cannabidiol (CBD) and Δ9-tetrahydrocannabivarin (THCV). Results from some of these studies have fostered the view that CBD and THCV modulate the effects of THC via direct blockade of cannabinoid CB1 receptors, thus behaving like first-generation CB1 [...]

Lire la suite

Endocannabinoid System as Therapeutic Target of PTSD : A Systematic Review, Luca Steardo, Jr. et al., 2021

Endocannabinoid System as Therapeutic Target of PTSD : A Systematic Review Luca Steardo, Jr., Elvira Anna Carbone, Giulia Menculini, Patrizia Moretti, Luca Steardo and Alfonso Tortorella Life, 2021, 11, 214. Doi : 10.3390/life11030214 Abstract : Post-Traumatic Stress Disorder (PTSD) is a complex disorder involving dysregulation of stress-related hormones and neurotransmitter systems. Research focused on the endocannabinoid system (eCBS) for anxiety and stress regulation, cognitive and emotional responses modulation and aversive memories extinction, leading to the hypothesis that it could represent a possible alternative treatment target for PTSD. In this systematic review, we summarize evidence about the efficacy and safety of medicinal cannabidiol (CBD), D9-tetrahydrocannabinol (D9-THC), and [...]

Lire la suite

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD) : A Systematic Review, Laura Orsolini et al., 2019

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD) : A Systematic Review Laura Orsolini, Stefania Chiappini, Umberto Volpe, Domenico De Berardis, Roberto Latini, Gabriele Duccio Papanti  and John Martin Corkery Medicina, 2019, 55, 525, 1-14 doi : 10.3390/medicina55090525 www.mdpi.com/journal/medicina Abstract : Background and Objectives : Post-traumatic stress disorder (PTSD) is a common psychiatric disorder resulting from a traumatic event, is manifested through hyperarousal, anxiety, depressive symptoms, and sleep disturbances. Despite several therapeutic approaches being available, both pharmacological and psychological, recently a growing interest has developed in using cannabis and synthetic cannabinoids stems from their consideration as more efficient and better tolerated alternatives [...]

Lire la suite

The Cannabis sativa Versus Cannabis indica Debate : An Interview with Ethan Russo, Daniele Piomelli  and Ethan B. Russo, 2016

The Cannabis sativa Versus Cannabis indica Debate : An Interview with Ethan Russo, MD Daniele Piomelli  and Ethan B. Russo Cannabis and Cannabinoid Research, 2016, Volume 1.1, 44-46. Doi : 10.1089/can.2015.29003.ebr   Dr. Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Medical Director of PHYTECS, a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system. Previously, from 2003 to 2014, he served as Senior Medical Advisor and study physician to GW Pharmaceuticals for three Phase III clinical trials of Sativex for alleviation of cancer pain unresponsive to optimized opioid treatment and studies of Epidiolex for intractable epilepsy. He has held [...]

Lire la suite